Advertisement
CRL vs TMO
Which Stock Would AI Choose? Charles River Laboratories (CRL) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- CRL has demonstrated stronger recent momentum, with shares rising over 20% in the past month compared to approximately 12% for TMO.
- Both companies operate in the life sciences sector, with CRL focused on research models and services and TMO providing a broader portfolio of instruments, reagents, and services.
- TMO maintains a significantly larger market capitalization of approximately $198 billion versus roughly $11 billion for CRL.
- TMO is scheduled to report second-quarter 2026 earnings on July 23, 2026, providing a near-term catalyst for sentiment.
- Relative performance in recent market activity highlights contrasts in volatility and sector positioning between the two stocks.
- Market sentiment appears influenced by broader life sciences recovery trends, with CRL showing more pronounced short-term gains.
Introduction
This comparison examines CRL and TMO to help traders and investors evaluate relative positioning within the life sciences industry. Both stocks serve clients in pharmaceutical, biotechnology, and academic research, making the analysis relevant for those seeking exposure to healthcare innovation and scientific tools. The review focuses on recent performance, business models, and observable market factors to support informed decision-making in the current environment.
CRL Overview and Recent Performance
Charles River Laboratories International, Inc. (CRL) provides research models, preclinical services, and support for drug discovery and development. In recent market activity, the stock has exhibited notable upward movement, with gains exceeding 20% over the past month amid broader sector interest. Performance has been supported by demand for research services and positive sentiment around life sciences spending. Factors influencing recent behavior include company-specific operational updates and overall market conditions affecting research and development budgets.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instruments, reagents, consumables, and laboratory services. The stock has recorded approximately 12% gains in the past month, alongside a year-to-date return near 8% in available data. Recent activity reflects anticipation ahead of the July 23, 2026, second-quarter earnings release, with expectations for revenue around $11.68 billion. Broader influences include steady demand across end markets and positioning within the larger healthcare tools sector.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI trading bots that trade thousands of different tickers, only the highest-performing and most suitable ones for current environments are featured in this section. Available bots display varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with statistics such as win rates, profit factors, and drawdowns typically ranging across wide intervals depending on the specific bot. This resource provides traders with data-driven insights into automated strategies. Explore the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
CRL and TMO differ in scale and focus: CRL specializes in research models and outsourced services with a narrower client base, while TMO offers diversified instruments and broader global reach. Growth drivers for CRL center on preclinical demand, whereas TMO benefits from recurring revenue across multiple scientific applications. Recent momentum favors CRL on a percentage basis, though TMO provides greater liquidity and stability due to its larger size. Risk factors include sector cyclicality for both, with TMO facing additional exposure to capital equipment cycles. Market sentiment reflects these contrasts, with CRL showing sharper short-term moves and TMO demonstrating more measured responses to earnings expectations.
Tickeron AI Verdict
Based on observable factors such as recent trend consistency and relative momentum, Tickeron’s AI would currently assign a probabilistic edge to CRL over TMO. Stronger percentage gains in recent weeks and positioning within research services provide supportive signals, though the larger scale and upcoming earnings visibility for TMO introduce counterbalancing considerations. This assessment remains data-dependent and subject to evolving market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a Buy and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- CRL’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- CRL’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
CRL (@Medical Specialties) experienced а +7.36% price change this week, while TMO (@Medical Specialties) price change was +9.50% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.21%. For the same industry, the average monthly price growth was +0.59%, and the average quarterly price growth was +9.72%.
Reported Earning Dates
CRL is expected to report earnings on Aug 05, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+0.21% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| CRL | TMO | CRL / TMO | |
| Capitalization | 11.3B | 214B | 5% |
| EBITDA | 291M | 11.7B | 2% |
| Gain YTD | 17.706 | -0.318 | -5,571% |
| P/E Ratio | 577.05 | 31.04 | 1,859% |
| Revenue | 4.03B | 45.2B | 9% |
| Total Cash | 192M | 1.12B | 17% |
| Total Debt | 3.06B | 43.2B | 7% |
CRL | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 94 | 62 | |
PRICE GROWTH RATING 1..100 | 7 | 42 | |
P/E GROWTH RATING 1..100 | 2 | 36 | |
SEASONALITY SCORE 1..100 | n/a | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is significantly better than the same rating for CRL (89) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew significantly faster than CRL’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as CRL (100) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to CRL’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as CRL (94) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to CRL’s over the last 12 months.
CRL's Price Growth Rating (7) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (42) in the Medical Specialties industry. This means that CRL’s stock grew somewhat faster than TMO’s over the last 12 months.
CRL's P/E Growth Rating (2) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (36) in the Medical Specialties industry. This means that CRL’s stock grew somewhat faster than TMO’s over the last 12 months.
| CRL | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 65% | 3 days ago 57% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Advances ODDS (%) | 25 days ago 69% | 2 days ago 62% |
| Declines ODDS (%) | 4 days ago 72% | 4 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 58% |
Advertisement